197 related articles for article (PubMed ID: 21047304)
1. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.
Wang LM; Ren DM
Mini Rev Med Chem; 2010 Oct; 10(11):1058-70. PubMed ID: 21047304
[TBL] [Abstract][Full Text] [Related]
2. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
3. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Tan AR; Swain SM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):77-85. PubMed ID: 12138401
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.
Kelland LR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2903-11. PubMed ID: 11093360
[TBL] [Abstract][Full Text] [Related]
6. [A novel small molecule cyclin-dependent kinase inhibitor flavopiridol in cancer therapy].
Song Y; Shen J
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):862-4. PubMed ID: 15949412
[No Abstract] [Full Text] [Related]
7. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitors.
Dai Y; Grant S
Curr Opin Pharmacol; 2003 Aug; 3(4):362-70. PubMed ID: 12901944
[TBL] [Abstract][Full Text] [Related]
10. [Flavopiridol, a cyclin-dependent kinase inhibitor].
Lansiaux A; Bailly C
Bull Cancer; 2000 Oct; 87(10):697-701. PubMed ID: 11084532
[No Abstract] [Full Text] [Related]
11. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
12. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
Senderowicz AM
Oncologist; 2002; 7 Suppl 3():12-9. PubMed ID: 12165651
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Senderowicz AM
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
Schwartz GK; Ilson D; Saltz L; O'Reilly E; Tong W; Maslak P; Werner J; Perkins P; Stoltz M; Kelsen D
J Clin Oncol; 2001 Apr; 19(7):1985-92. PubMed ID: 11283131
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
18. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
Liu X; Shi S; Lam F; Pepper C; Fischer PM; Wang S
Int J Cancer; 2012 Mar; 130(5):1216-26. PubMed ID: 21484792
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of cyclin-dependent kinase modulators.
Senderowicz AM; Sausville EA
J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
